Sanofi (SAN) PT Set at €93.00 by Deutsche Bank
A number of other equities analysts have also weighed in on the company. Berenberg Bank set a €97.00 ($115.48) price objective on Sanofi and gave the stock a neutral rating in a research note on Thursday, November 2nd. set a €78.00 ($92.86) price objective on Sanofi and gave the stock a neutral rating in a research note on Friday, November 3rd. UBS Group set a €82.00 ($97.62) price objective on Sanofi and gave the stock a neutral rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. reissued a neutral rating and set a price objective on shares of Sanofi in a research note on Thursday, November 2nd. Finally, Morgan Stanley set a €92.00 ($109.52) price objective on Sanofi and gave the stock a buy rating in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the company. Sanofi currently has an average rating of Hold and an average target price of €86.88 ($103.42).
Shares of Sanofi (EPA SAN) opened at €70.83 ($84.32) on Friday. Sanofi has a 12-month low of €71.06 ($84.60) and a 12-month high of €92.97 ($110.68). The company has a market capitalization of $89,470.00 and a P/E ratio of 19.62.
ILLEGAL ACTIVITY WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/23/sanofi-san-pt-set-at-93-00-by-deutsche-bank.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.